small
protein
conjug
protein
includ
posttransl
modif
often
control
cellular
signal
degrad
modifi
protein
ubiquitinlik
protein
ubl
protein
small
ubiquitinlik
modifi
sumo
interferonstimul
gene
adopt
fold
characterist
ubiquitin
relat
protein
deubiquityl
enzym
drug
discoveri
emerg
opportun
jeanin
harrigan
xavier
jacq
niall
martin
stephen
p
jackson
abstract
decad
nobel
prize
award
discoveri
ubiquitinproteasom
system
clinic
approv
proteasom
ubiquitin
ligas
inhibitor
firstgener
deubiquityl
enzym
dub
inhibitor
approach
clinic
trial
howev
although
knowledg
physiolog
pathophysiolog
role
dub
evolv
tremend
clinic
develop
select
dub
inhibitor
challeng
review
discuss
issu
highlight
recent
advanc
understand
dub
enzymolog
biolog
well
technolog
improv
contribut
current
interest
dub
therapeut
target
diseas
rang
oncolog
neurodegener
cancer
amplifi
certain
glioblastoma
breast
ovarian
cancer
cyld
commonli
mutat
cylindromatosi
deregul
mjdfamili
dub
also
link
diseas
associ
polyglutamin
amplif
exampl
expans
dna
cag
trinucleotid
repeat
ataxin
caus
machadojoseph
diseas
also
known
spinocerebellar
ataxia
furthermor
mutat
jamm
famili
member
associ
molecul
domain
stam
amsh
also
known
stambp
caus
microcephalycapillari
malform
syndrom
grow
interest
exploit
compon
ubiquityl
machineri
therapeut
target
although
strong
progress
develop
smallmolecul
inhibitor
ubiquitin
ubl
enzym
highli
pleiotrop
natur
mean
drug
like
confin
acut
set
treatment
aggress
cancer
given
greater
number
divers
dub
offer
potenti
develop
drug
specif
effect
particular
group
divers
enzym
welldefin
catalyt
cleft
dub
intrins
attract
potenti
drug
target
howev
discuss
recent
develop
select
dub
inhibitor
natur
review
drug
discoveri
enzym
activ
ubiquitin
atpdepend
manner
result
coval
thioester
linkag
ubiquitin
cystein
residu
ubiquitin
transfer
conjug
enzym
form
thioester
linkag
catalyt
cystein
final
ligas
assist
directli
catalys
transfer
ubiquitin
substrat
usual
via
lysin
side
chain
exampl
hect
homolog
carboxyl
terminu
rbr
ringbetweenr
ligas
shown
subsequ
round
ubiquitin
molecul
conjug
ntermin
amino
group
lysin
ubiquitin
form
chain
deubiquityl
enzym
dub
remov
ubiquitin
molecul
substrat
process
ubiquitin
precursor
gener
free
ubiquitin
pool
b
dub
phylogenet
tree
sequenc
fulllength
dub
senp
sentrinsumospecif
proteas
protein
align
cobalt
constraintbas
multipl
align
tool
comput
tool
multipl
protein
sequenc
subsequ
visual
figtre
regard
note
variou
relat
human
dub
exist
amsh
associ
molecul
domain
stam
amshlp
amshlik
proteas
ataxin
protein
cezann
cellular
zinc
finger
protein
csn
signalosom
complex
subunit
cyld
cylindromatosi
desi
desumoyl
isopeptidas
eukaryot
translat
initi
factor
jamm
mpn
famili
josd
josephin
domain
mindi
motifinteract
ubiquitincontain
novel
dub
famili
mjd
machadojosephin
domaincontain
proteas
otud
otu
domaincontain
protein
premrnaprocess
splice
factor
uchl
ubiquitin
carboxytermin
hydrolaselik
usp
ubiquitinspecif
proteas
valosincontain
protein
complexinteract
protein
protein
complex
recogn
degrad
polyubiquityl
protein
regulatori
subunit
contain
atpaseand
ubiquitinbind
site
catalyt
core
contain
proteas
deubiquityl
enzym
dub
protein
remov
ubiquitin
substrat
protein
cleav
ubiquitin
precursor
type
protein
normal
restrict
prolifer
invas
properti
normal
cell
mutat
lossofexpress
tumour
suppressor
lead
cancer
progress
type
protein
normal
control
growth
differenti
surviv
cell
whose
mutat
express
abnorm
high
level
promot
tumorigenesi
type
enzym
hydrolys
amid
bond
occur
outsid
main
chain
polypeptid
chain
limit
insuffici
understand
dub
biolog
difficulti
establish
robust
biochem
assay
suitabl
compound
screen
limit
cellular
vivo
model
assess
dub
activ
inhibit
pleiotrop
natur
variou
smallmolecul
dub
inhibitor
mani
issu
larg
overcom
rate
progress
dub
drug
discoveri
acceler
past
year
variou
select
compound
describ
character
academ
group
compani
review
discuss
dub
deregul
affect
human
diseas
particularli
cancer
neurodegener
inflamm
tabl
highlight
therapeut
potenti
pharmacolog
modul
dub
activ
recent
advanc
assay
develop
screen
technolog
enabl
research
drug
develop
overcom
recurr
challeng
clinic
translat
dub
inhibitor
also
discuss
accumul
evid
implic
dub
tumorigenesi
multipl
level
fig
first
dub
cyld
describ
display
intrins
oncogen
tumour
suppressor
activ
second
dub
connect
control
key
epigenet
chang
promot
tumour
develop
third
deubiquityl
activ
variou
dub
report
regul
level
andor
activ
variou
oncogen
tumour
suppressor
protein
fourth
dub
modul
therapeut
relev
cellular
compon
process
up
exampl
also
known
stem
cell
renew
exampl
dna
damag
respons
ddr
dna
repair
exampl
immunooncolog
exampl
receptor
tyrosin
kinas
exampl
consequ
describ
detail
variou
dub
emerg
attract
target
develop
novel
cancer
therapi
success
target
proteasom
cancer
therapi
underlin
clinic
success
bortezomib
broadli
act
proteasom
inhibitor
refractori
multipl
myeloma
mantl
cell
myeloma
howev
three
dub
associ
proteasom
function
also
known
repres
specif
anticanc
target
facilit
degrad
proteasometarget
substrat
special
dub
remov
ubiquitin
moieti
would
otherwis
imped
entri
proteasom
catalyt
core
jamm
metalloproteas
highlight
potenti
therapeut
target
studi
show
level
invers
correl
surviv
patient
multipl
myeloma
deplet
impair
prolifer
multipl
myeloma
cell
addit
nuclear
elev
hepatocellular
carcinoma
correl
overexpress
tumour
growth
also
report
regul
ubiquityl
stabil
oncogen
receptor
tyrosin
kinas
ref
furthermor
connect
promot
cellular
respons
dna
doublestrand
break
particularli
process
homolog
recombin
inhibit
could
potenti
sensit
cancer
cell
dnadamag
agent
andor
preferenti
kill
cancer
cell
reli
strongli
homolog
recombin
anoth
potenti
anticanc
therapeut
target
primarili
associ
proteasom
regulatori
subunit
potenti
ubiquitin
recycl
constitut
activ
revers
associ
subunit
also
known
enhanc
activ
inhibit
proteasom
degrad
ubiquitinprotein
conjug
trim
ubiquitin
chain
protein
substrat
degrad
express
upregul
nonsmallcel
lung
cancer
especi
adenocarcinoma
level
reportedli
elev
ovarian
cancer
sampl
line
connect
sever
import
signal
pathway
exampl
substrat
akt
mediat
intracellular
signal
growth
factor
modul
dishevel
protein
key
posit
regul
wnt
signal
like
dub
revers
interact
proteasom
bind
receptor
also
known
manner
enhanc
isopeptidas
activ
key
function
remov
distal
ubiquitin
moieti
polyubiquityl
protein
therebi
liber
protein
destruct
facilit
destruct
certain
substrat
describ
induc
nitric
oxid
synthas
nuclear
therefor
seem
like
suppress
destruct
certain
protein
promot
degrad
other
notabl
rna
interfer
studi
show
deplet
either
alon
detect
effect
cell
growth
proteasom
structur
proteolyt
capac
acceler
cellular
protein
degrad
contrast
deplet
dub
decreas
protein
degrad
suggest
overlap
function
overexpress
epitheli
ovarian
cancer
associ
advanc
tumour
progress
poor
clinic
outcom
also
overexpress
hepatocellular
carcinoma
shown
promot
cell
migrat
invas
proteasomeassoci
dub
repres
attract
drug
target
inhibit
might
substanti
effect
cancer
cell
physiolog
fewer
toxic
seen
drug
target
core
proteasom
catalyt
function
inde
tabl
advanc
report
dub
inhibitor
recent
phase
trial
suspend
treatment
multipl
myeloma
solid
tumour
describ
target
ref
ringexpand
version
compound
also
known
identifi
cellbas
screen
look
compound
induc
apoptosi
cell
treat
accumul
polyubiquitin
chain
claim
target
possibl
also
ref
compound
report
revers
reason
select
dub
cellbas
activ
probe
assay
median
inhibitori
concentr
ic
purifi
proteasom
dub
activ
display
strong
activ
test
variou
vivo
solid
tumour
model
includ
multipl
myeloma
remain
seen
whether
select
suffici
deliv
promis
nextgener
proteasom
inhibitor
cleav
bioscienc
also
publish
seri
patent
applic
describ
compound
inhibit
jamm
proteas
provid
potenti
angl
develop
select
inhibitor
tabl
one
hallmark
cancer
downregul
loss
deregul
certain
dna
repair
ddr
pathway
andor
strong
relianc
pathway
dna
repair
ddr
mechan
regul
posttransl
modif
ubiquityl
mani
dub
strongli
link
process
one
exampl
dub
identifi
regul
fanconi
anaemia
group
protein
ubiquityl
key
protein
involv
fanconi
anaemia
pathway
dna
crosslink
repair
influenc
accumul
fanconi
anaemia
core
complex
dna
damag
site
deubiquityl
cell
cycledepend
manner
also
remov
monoubiquitin
prolifer
cell
nuclear
antigen
pcna
dna
replic
compon
also
function
dna
repair
translat
synthesi
activ
includ
involv
feedback
loop
limit
ddr
protein
kinas
activ
regul
cellular
differenti
osteosarcoma
cell
deubiquityl
henc
affect
stabil
inhibitor
dnabind
protein
vitro
activ
greatli
stimul
factor
also
known
enhanc
catalyt
turnov
k
cat
affin
k
monoubiquityl
substrat
select
inhibitor
submicromolar
potenc
identifi
one
pimozid
shown
resensit
platinumresist
nonsmallcel
lung
cancer
cell
promot
pcna
monoubiquityl
howev
although
studi
indic
ontarget
effect
dub
select
profil
suggest
pimozid
might
less
select
initi
describ
optim
certain
screen
hit
gener
addit
molecul
notabl
select
pyrimidin
core
compound
tabl
molecul
alloster
block
complex
format
ref
potenti
cisplatin
cytotox
increas
pcna
monoubiquityl
cell
far
howev
littl
progress
made
advanc
select
inhibitor
clinic
develop
anoth
dub
link
dna
repair
initi
describ
form
complex
ddr
tumour
suppressor
breast
cancer
type
suscept
protein
promot
dna
doublestrand
break
repair
pathway
homolog
recombin
deplet
shown
sensit
cell
olaparib
also
known
inhibit
ddr
enzym
poli
adpribos
polymeras
recent
interact
partner
local
function
cooper
dna
repair
shown
ubiquitin
control
ubiquityl
suppress
interact
manner
counteract
ref
current
report
inhibitor
topoisomeras
inhibitor
mitoxantron
tabl
although
author
report
low
nanomolar
potenc
pancreat
ductal
adenocarcinoma
cell
surviv
model
develop
compound
report
given
appar
amen
smallmolecul
inhibit
notabl
dub
close
relat
recent
shown
involv
ddr
promot
earli
stage
homolog
recombin
maintain
dna
replic
fork
stabil
dna
damag
checkpoint
respons
regul
protein
claspin
phase
may
repres
anoth
potenti
therapeut
target
shown
affect
radiosensit
glioblastoma
cell
myeloid
cell
leukaemia
depend
independ
mechan
bestdescrib
inhibitor
tabl
identifi
screen
janu
kinas
inhibitor
shown
inhibit
well
dub
shown
mass
spectrometri
coval
mechan
action
compound
revers
variou
dub
report
connect
tumoursuppress
oncogen
function
may
therefor
repres
potenti
therapeut
target
regul
sever
dub
link
regul
tumour
suppressor
protein
pivot
role
cellular
stress
respons
lost
mutat
mani
cancer
human
doubl
minut
also
known
ringtyp
ubiquitin
ligas
key
neg
regul
abil
ubiquityl
target
degrad
cleav
ubiquitin
chain
counteract
proteasom
degrad
lead
suppress
increas
ubiquityl
degrad
theori
inhibit
therefor
trigger
degrad
stabil
ultim
activ
apoptot
pathway
tumour
cell
addit
target
also
describ
phosphatas
tensin
homologu
pten
forkhead
box
protein
ref
suggest
altern
therapeut
mechan
inhibitor
also
recent
shown
promot
dna
replic
via
act
dub
ubl
sumo
first
publish
submicromolar
inhibitor
ref
shown
rather
nonspecif
inhibitor
dub
recent
moreselect
amidotetrahydroacridin
deriv
identifi
although
exhibit
fairli
low
potenc
despit
shown
coval
bind
catalyt
cy
residu
prefer
cysteinyl
group
stabil
promot
arrest
apoptosi
cell
progenra
thiophen
chemic
seri
also
provid
rel
nonspecif
inhibitor
includ
compound
ref
multipl
myeloma
cell
stabil
inhibit
tumour
growth
wherea
anim
model
well
toler
inhibit
tumour
growth
prolong
surviv
recent
vivo
studi
use
within
orthotop
neuroblastoma
mous
model
show
statist
signific
inhibit
xenograft
growth
find
encourag
littl
known
bind
mode
compound
whether
optim
druglik
entiti
recent
almac
discoveri
genentech
report
fragmentbas
screen
provid
hit
start
point
discoveri
programm
optim
one
hit
assist
xray
crystallographi
produc
noncoval
highli
select
inhibitor
tabl
stabil
also
recent
report
regul
dub
ref
shown
bind
deubiquityl
result
stabil
delet
result
destabil
wherea
ectop
express
induc
express
target
gene
promot
apoptosi
whether
inhibitor
could
exploit
treat
cancer
diseas
remain
establish
anoth
dub
recent
connect
function
togeth
protein
promot
transcript
respons
furthermor
mutat
human
cancer
cell
report
antagon
tumour
suppressor
fbox
domaincontain
protein
highlight
potenti
inhibitor
variou
tumour
especi
colorect
cancer
also
report
antagon
ubiquitindepend
degrad
oncogen
product
myc
well
jun
notch
although
inhibitor
yet
report
seem
like
drug
discoveri
activ
underway
anoth
tumour
suppressor
link
dub
activ
von
hippellindau
vhl
protein
ubiquityl
hypoxiainduc
factor
cellular
oxygen
level
normal
lead
degrad
also
known
report
de
ubiquityl
number
protein
includ
deubiquityl
prevent
proteasom
degrad
allow
transcript
hypox
respons
gene
thu
inhibit
potenti
suppress
prolifer
hypox
tumour
cell
glaxosmithklin
gsk
present
brief
detail
search
inhibitor
confer
ref
tabl
egfr
ubiquityl
serv
signal
deliv
membran
receptor
cell
surfac
lysosom
mammalian
cell
mechan
intens
studi
epiderm
growth
factor
receptor
egfr
upon
egf
bind
activ
egfr
rapidli
intern
transport
via
earli
late
endosom
lysosom
egfr
degrad
also
known
ubpi
deubiquityl
egfr
earli
endosom
rescu
egfr
degrad
sever
tumour
includ
glioblastoma
lung
breast
cancer
egfr
amplifi
mutat
tyrosin
kinas
domain
result
deregul
receptor
signal
drive
uncontrol
prolifer
tumour
cell
inhibitor
exampl
similar
structur
class
identifi
ref
report
tabl
moreov
deriv
compound
shown
efficaci
mous
model
lung
cancer
regul
transform
growth
pathway
thought
import
prolifer
glioblastoma
cell
bind
ubiquitin
protein
ligas
complex
deubiquityl
stabil
type
receptor
lead
enhanc
signal
gene
amplifi
glioblastoma
breast
ovarian
cancer
high
express
correl
high
activ
deplet
reduc
oncogen
capac
patientderiv
gliomainiti
cell
owe
diminish
signal
suggest
therapeut
potenti
develop
inhibitor
addit
shown
deubiquityl
receptorregul
smad
rsmad
anoth
set
signal
pathway
compon
dub
normal
express
predominantli
neuron
neuroendocrin
tissu
highli
express
mani
cancer
express
correl
poor
prognosi
although
report
tumoursuppress
role
evid
support
role
oncogen
inde
transgen
mous
model
constitut
activ
sporad
tumour
develop
mani
tissu
moreov
vitro
tumorigenesi
studi
show
express
stimul
oncogenesi
invas
phenotyp
wherea
deplet
antitumour
effect
block
cell
migrat
lung
cancer
cell
line
precis
mechan
contribut
tumorigenesi
remain
unclear
although
report
suggest
contribut
cell
surviv
signal
cell
cycl
regulatori
cell
reg
cell
subpopul
cell
modul
immun
system
maintain
toler
selfantigen
prevent
autoimmun
diseas
cellular
organel
produc
atp
oxid
phosphoryl
process
elimin
damag
age
mitochondria
via
sequestr
hydrolyt
degrad
lysosom
regul
dna
repair
regul
pool
free
ubiquitin
way
affect
protein
degrad
function
inhibitor
describ
potent
isatin
oacyl
oxim
tabl
select
ref
addit
seri
pyridinon
identifi
moder
inhibitor
enzym
kinet
studi
reveal
compound
uncompetit
inhibitor
select
exhibit
inhibit
cystein
hydrolas
test
use
xray
crystallographi
weak
tripeptid
fluoromethyl
keton
inhibitor
subsequ
shown
bind
within
activ
site
irrevers
modifi
activesit
cystein
mission
therapeut
also
develop
sever
seri
potent
select
inhibitor
although
inhibitor
demonstr
antitumour
activ
vivo
induc
deplet
shown
caus
diseas
regress
orthotop
multipl
myeloma
mous
model
anoth
dub
associ
oncogenesi
catalyt
subunit
deubiquitylas
modul
saga
complex
bestcharacter
substrat
saga
complex
includ
sever
acetyl
site
histon
ubiquityl
site
histon
posttransl
modif
regul
gene
express
strong
link
oncogenesi
identifi
microarray
screen
part
deathfromcanc
signatur
highli
aggress
therapyresist
tumour
later
shown
act
oncogen
product
regul
cell
cycl
progress
prolifer
apoptosi
increas
express
connect
poor
prognosi
sever
cancer
includ
liver
colorect
breast
cancer
well
oesophag
squamou
cell
carcinoma
oral
squamou
cell
carcinoma
dub
activ
link
surviv
progress
cancer
inhibitor
may
provid
attract
prospect
new
therapi
given
role
ubiquitin
modif
dub
mani
inflammatori
process
see
well
renew
interest
target
immun
system
fight
cancer
antineoplast
potenti
therapeut
inhibit
dub
involv
immun
system
investig
among
posit
regul
stabil
crucial
transcript
factor
control
differenti
regulatori
cell
reg
cell
search
dub
contribut
stabil
cell
shown
upregul
activ
use
report
assay
furthermor
deplet
reg
cell
result
downregul
compromis
express
reg
signatur
gene
impair
suppress
activ
reg
cell
restrict
antitumour
immun
respons
promot
tumour
surviv
result
suggest
deplet
reg
cell
target
offer
promis
anticanc
immunotherapi
regard
mission
therapeut
investig
immunooncolog
target
develop
inhibitor
see
mission
therapeut
pipelin
inform
identif
ubiquitin
protein
aggreg
associ
neurodegen
pathologiessuch
neurofibrillari
tangl
alzheim
diseas
neuron
inclus
bodi
also
known
lewi
bodi
parkinson
diseas
intranuclear
inclus
hereditari
polyglutamin
expans
disordersha
prompt
much
interest
understand
ubiquityl
deubiquityl
affect
aggreg
dub
function
central
nervou
system
describ
detail
elsewher
therefor
focu
select
number
dub
connect
neurodegen
diseas
mitochondri
dysfunct
up
impair
describ
hallmark
age
implic
aetiopathogenesi
mani
agerel
diseas
particularli
neurodegen
disord
alzheim
diseas
parkinson
diseas
accord
connect
ubiquityl
close
link
mitochondri
function
up
maintain
mitochondri
homeostasi
regul
organel
dynam
mitochondri
proteom
mitophagi
convers
mitochondri
dysfunct
impair
cellular
protein
homeostasi
gener
oxid
damag
notabl
mutat
ubiquitin
ligas
parkin
causal
associ
certain
case
famili
parkinson
diseas
parkin
ubiquityl
mitochondri
compon
thu
promot
turnov
mitochondria
lysosomemedi
mitophagi
defect
mitophagi
accumul
defect
mitochondria
caus
enhanc
oxid
stress
could
underli
caus
parkinson
diseas
corollari
parkin
activ
inhibit
factor
counteract
parkin
could
provid
opportun
diseas
allevi
screen
dub
oppos
parkin
function
identifi
mitochondrionassoci
dub
antagonist
parkinmedi
mitophagi
deplet
significantli
decreas
mitochondri
number
cell
phenotyp
rescu
wildtyp
catalyt
inact
furthermor
deplet
vivo
provid
stress
protect
drosophila
melanogast
model
parkinson
diseas
line
find
deplet
human
hela
cell
led
elong
interconnect
mitochondria
suggest
role
regul
mitochondri
fusion
fission
current
model
invok
function
normal
physio
logic
condit
prevent
inappropri
mitophagi
howev
respons
stress
membran
depolar
parkin
recruit
mitochondria
promot
mitophagi
accordingli
condit
mitochondri
dysfunct
exampl
caus
defect
ax
j
hypomorph
allel
ataxia
mutat
ax
j
recess
neurolog
mutat
result
reduc
growth
ataxia
hindlimb
muscl
wast
mice
parkin
posit
regul
thought
counteract
clearanc
damag
mitochondria
lead
buildup
metabol
energet
defici
cell
thu
hypothes
context
certain
mitochondri
dysfunct
inhibit
would
therapeut
benefit
far
one
chemic
inhibitor
describ
tabl
induc
mitochondri
elong
mous
fibroblast
effect
cell
viabil
mission
therapeut
explor
inhibit
treatment
parkinson
diseas
mitochondri
disord
publish
sever
patent
applic
describ
inhibitor
two
dub
connect
mitophagi
notabl
deplet
found
delay
parkin
transloc
onto
depolar
mitochondria
well
mitochondri
clearanc
display
abil
remov
ubiquitin
chain
parkin
vitro
addit
shown
remov
ubiquitin
chain
protein
known
aggreg
often
ubiquityl
form
lewi
bodi
associ
neurodegen
diseas
parkinson
diseas
deplet
either
human
cell
melanogast
result
increas
lysosom
degrad
meanwhil
identifi
parkininteract
protein
coloc
mitochondria
hela
cell
overexpress
parkin
overexpress
wildtyp
catalyt
dead
strongli
inhibit
mitophagi
furthermor
deplet
endogen
enhanc
mitophagi
hela
cell
human
dopaminerg
neuron
cell
line
primari
fibroblast
human
patient
deubiquityl
parkin
basal
condit
cell
treat
mitochondri
depolar
agent
deplet
also
seem
affect
parkin
transloc
mitochondria
although
oppos
parkinmedi
mitochondri
ubiquityl
final
loss
melanogast
found
rescu
locomotor
defect
accumul
dysfunct
mitochondria
flight
muscl
parkinknockout
fli
collect
find
highlight
potenti
inhibitor
parkinson
diseas
perhap
diseas
associ
mitochondri
dysfunct
highlight
connect
parkinson
diseas
dub
shown
interact
parkin
manner
counteract
parkin
autoubiquityl
addit
recent
shown
remov
ubiquitin
chain
protein
aggreg
accumul
lewi
bodi
hallmark
parkinson
diseas
describ
remov
ubiquitin
certain
substrat
target
proteasom
thu
rescu
substrat
degrad
maintain
pool
free
ubiquitin
tabl
revers
smallmolecul
inhibitor
shown
target
catalyt
site
promot
degrad
sever
overexpress
protein
tau
tar
dnabind
protein
whose
accumul
link
neurodegen
diseas
notabl
promot
degrad
murin
embryon
fibroblast
cell
suggest
compound
function
specif
furthermor
reduc
accumul
menadioneinduc
oxid
protein
amelior
menadioneor
hydrogen
peroxideinduc
cell
death
human
cell
proteostasi
therapeut
collabor
biogen
develop
inhibitor
clearanc
aggregationpron
protein
includ
parkinson
diseas
tau
alzheim
diseas
see
proteostasi
pipelin
inform
publish
sever
patent
applic
describ
inhibitor
despit
grow
interest
therapeut
target
cancer
neurodegener
fact
loss
caus
sever
morbid
postnat
lethal
requir
investig
especi
regard
role
neuromuscular
junction
neuromuscular
phenotyp
ax
j
mice
rescu
neuronalspecif
express
ref
furthermor
extent
contribut
clearanc
protein
involv
neurodegener
vivo
remain
controversi
develop
use
inhibitor
diseaserelev
model
may
shed
light
issu
hope
defin
potenti
therapeut
window
inhibit
diseas
set
syndrom
congenit
disord
driven
triplic
human
chromosom
gene
resid
report
regul
cell
cycl
progress
gene
express
deubiquityl
histon
defect
haematopoiet
stem
cell
selfrenew
mous
model
syndrom
rescu
reduc
express
level
similar
control
mice
addit
overexpress
normal
human
fibroblast
neural
progenitor
led
reduc
cell
expans
similar
strong
prolifer
defect
observ
fibroblast
individu
syndrom
thu
key
regul
control
stem
cell
selfrenew
senesc
syndrom
suggest
inhibitor
might
provid
therapeut
benefit
individu
pathogen
recogn
sever
famili
pattern
recognit
receptor
activ
variou
signal
transduct
cascad
via
rigilik
receptor
rlr
nucleotidebind
oligomer
domainlik
receptor
nlr
tolllik
receptor
tlr
signal
event
mediat
induct
inflamm
import
recruit
immun
cell
site
infect
ubiquityl
critic
posttransl
modif
process
nondegrad
ubiquitin
chain
mediat
key
upstream
event
recruit
cytokin
member
class
immunoregulatori
protein
interleukin
interferon
secret
cell
especi
cell
immun
system
h
cell
activ
cell
link
defenc
variou
type
pathogen
commonli
defin
product
particular
cytokin
bestcharacter
effector
cell
subset
includ
h
h
h
cell
kinas
kinas
ikk
complex
respect
polyubiquityl
activ
complex
phosphoryl
subunit
key
serin
residu
activ
loop
result
ikk
activ
transcript
activ
target
gene
includ
mediat
immun
inflammatori
respons
well
feedback
inhibitor
pathway
neg
regul
includ
dub
cleav
linear
ubiquitin
chain
also
known
cyld
otu
domaincontain
deubiquitinas
linear
linkag
specif
otulin
also
known
gumbi
probabl
bestcharacter
dub
link
inflamm
dub
play
key
part
restrict
tlr
signal
maintain
immun
homeostasi
deubiquityl
signal
factor
essenti
modul
nemo
receptorinteract
serinethreonineprotein
kinas
tumour
necrosi
factor
tnf
receptorassoci
factor
addit
bind
polyubiquitin
chain
zinc
finger
domain
allow
interact
ubiquityl
nemo
ubiquitininduc
recruit
nemo
suffici
block
ikk
phosphoryl
upstream
kinas
prevent
activ
thu
defici
promot
local
system
inflamm
vivo
underscor
inactiv
mutat
connect
inflammatori
autoimmun
syndrom
cyld
anoth
dub
known
neg
regul
ubiquityl
one
major
rlr
interferon
ifn
regul
gene
induct
cyld
bind
therebi
inhibit
ubiquityl
signal
function
cyld
also
inhibit
ubiquityl
contribut
neg
regul
ifn
respons
consist
cyld
defici
caus
constitut
activ
dendrit
cell
despit
enhanc
signal
cylddefici
cell
mice
suscept
vesicular
stomat
viru
infect
due
attenu
signal
antivir
gene
express
induc
suggest
posit
role
cyld
regul
type
ifn
receptor
function
ubiquitin
chain
gener
linear
ubiquitin
chain
assembl
complex
lubac
consist
haemoxid
ubiquitin
ligas
also
known
protein
hoip
also
known
shankassoci
rh
domaininteract
protein
sharpin
lubac
recruit
mani
immun
receptor
ubiquityl
target
protein
includ
receptorassoci
kinas
irak
nemo
genet
loss
lubac
compon
lead
immunodefici
inflammatori
phenotyp
mice
mutat
lubac
compon
also
caus
inflammatori
condit
human
henc
loss
ubiquitin
chain
imbal
immun
signal
otulin
dub
known
specif
cleav
linkag
accordingli
homozyg
hypomorph
mutat
human
otulin
recent
shown
caus
potenti
fatal
autoinflammatori
condit
term
otulinrel
autoinflammatori
syndrom
similar
ubiquitin
ubl
ifnstimul
gene
key
role
cellular
signal
respons
pathogen
conjug
variou
cellular
substrat
revers
ifninduc
isopeptidas
upregul
viral
infect
type
type
iii
ifn
lipopolysaccharid
genotox
stress
addit
isopeptidas
activ
neg
regul
type
type
iii
ifn
signal
block
subunit
interferon
receptor
debilit
autoimmun
diseas
rang
genet
componentssuch
crohn
diseas
diabet
mellitu
type
grave
diseas
rheumatoid
arthriti
sporad
condit
includ
coeliac
diseas
inflammatori
bowel
diseas
multipl
sclerosi
psoriasi
system
lupu
erythematosu
addit
chronic
inflammatori
diseas
character
prolong
persist
proinflammatori
state
includ
autoimmun
diseas
well
metabol
syndrom
neurodegen
diseas
chronic
obstruct
pulmonari
diseas
cardiovascular
diseas
follow
pattern
recognit
receptor
stimul
dendrit
cell
secret
variou
cytokin
regul
differenti
cell
differ
subset
shown
stabil
nuclear
receptor
retinoidrel
orphan
h
cell
propos
possibl
therapeut
target
rheumatoid
arthriti
one
report
show
highli
express
h
cell
deplet
result
decreas
well
express
addit
use
report
inhibitor
vialinin
tabl
also
diminish
express
furthermor
express
mrna
shown
significantli
elev
cell
patient
rheumatoid
arthriti
compar
healthi
control
provid
evid
role
rheumatoid
arthriti
trabid
also
known
requir
tlrmediat
express
inflammatori
cytokin
dendrit
cell
propos
trabid
deubiquityl
stabil
histon
demethylas
jumonji
domaincontain
protein
also
known
regul
histon
modif
promot
facilit
recruit
famili
member
rel
condit
delet
dendrit
cell
impair
product
gener
h
h
subset
inflammatori
cell
render
mice
refractori
induct
experiment
autoimmun
encephalomyel
eae
anoth
dub
associ
activ
h
cell
although
dub
extens
studi
context
viral
infect
regul
interact
requir
h
cell
differenti
autoimmun
respons
consist
mice
resist
eae
cell
receptor
signal
shown
facilit
dub
cellular
zinc
finger
protein
cezann
also
known
bind
deubiquityl
protein
thu
prevent
interact
neg
regulatori
phosphatas
cyto
plasmic
protein
tyrosin
kinas
play
crucial
part
cell
signal
recruit
phosphoryl
site
cell
receptor
subsequ
phosphoryl
src
kinas
lck
phosphoryl
requir
full
activ
downstream
phosphoryl
adaptor
protein
facilit
cell
signal
addit
cezannedefici
mice
exhibit
attenu
cell
respons
bacteri
infect
refractori
eae
young
mice
similar
naiv
memorylik
cell
compar
wildtyp
mice
older
mice
defici
cezann
reduc
h
cell
subset
similar
h
cell
h
cell
capac
caus
inflamm
autoimmun
diseas
develop
differenti
function
h
cell
driven
tbox
transcript
factor
tbet
also
known
promot
h
immun
respons
primarili
promot
express
cytokin
dub
shown
deubiquityl
stabil
tbet
result
enhanc
secret
addit
mrna
express
found
elev
peripher
blood
mononuclear
cell
patient
asthma
compar
healthi
donor
although
current
unclear
mani
dub
involv
regul
immun
respons
possibl
differ
dub
function
distinct
cell
type
mani
publish
studi
base
cell
line
overexpress
system
express
endo
genou
dub
variou
immun
cell
import
area
futur
investig
similarli
gener
genet
model
develop
inhibitor
cezann
trabid
help
determin
therapeut
potenti
describ
grow
interest
dub
potenti
therapeut
target
variou
infecti
diseas
man
anim
potenti
explor
develop
compound
inhibit
activ
pathogenencod
dublik
protein
target
host
cell
dub
control
pathogen
life
cycl
infect
ubiquityl
import
modul
proteinprotein
interact
includ
activ
innat
immun
signal
pathway
perhap
surpris
variou
virus
gene
dub
use
strategi
inhibit
ubiquitinand
antivir
pathway
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
two
six
known
human
coronavirus
highli
pathogen
potenti
humantohuman
transmiss
contain
papainlik
cystein
proteas
term
sarscov
plpro
merscov
plpro
respect
addit
process
viral
polyprotein
proteas
remov
ubiquitin
host
cell
factor
result
antagon
host
antivir
immun
respons
henc
sarscov
plpro
merscov
plpro
propos
import
antivir
target
xray
structur
proteas
shown
structur
similar
usp
famili
dub
otu
domaincontain
proteas
divers
rna
virus
includ
nairovirus
crimeancongo
haemorrhag
fever
viru
dugb
viru
papainlik
proteas
domain
arteriviru
equin
arter
viru
proteas
pro
domain
tymoviru
turnip
yellow
mosaic
viru
hydrolys
ubiqu
itin
cellular
target
protein
mani
positivestrand
rna
virus
includ
arterivirus
tymovirus
encod
polyprotein
posttransl
cleav
intern
proteas
domain
accord
arteriviru
tymoviru
prodomaincontain
proteas
crucial
requir
viral
replic
due
primari
role
poli
protein
matur
thu
viral
otu
domaincontain
proteas
may
repres
promis
therapeut
target
bacteria
use
repertoir
effector
protein
target
eukaryot
ubiquitin
system
promot
bacteri
pathogen
proteas
activ
human
bacteri
pathogen
includ
salmonella
enterica
serovar
typhimurium
ssel
escherichia
coli
elad
shigella
flexneri
shice
chlamydia
trachomati
rickettsia
bellii
rickc
legionella
pneumophila
subsp
pneumophila
legc
recent
character
legc
show
proteolyt
activ
ssel
elad
shice
demonstr
ubiquitinspecif
proteas
activ
wherea
rickc
cleav
ubiquitin
lesser
extent
peptid
interestingli
dub
encod
human
pathogen
show
strong
prefer
ubiquitin
chain
target
chain
later
time
point
higher
enzym
concentr
therefor
bacteri
dub
potenti
therapeut
target
addit
express
dub
target
host
function
similar
virus
bacteria
eukaryot
parasit
also
possess
ubl
pathway
use
ubiquitinbas
activ
probe
identifi
dub
alloster
bind
site
activ
site
enzym
result
modul
enzymat
activ
plasmodium
falciparum
led
identif
shown
deubiquityl
activ
also
abil
remov
adduct
ubl
ref
investig
parasit
toxoplasma
gondii
use
similar
strategi
identifi
four
dub
one
ortholog
mammalian
ref
structur
studi
explain
dual
specif
enzym
found
requir
parasit
surviv
distinct
differ
ubiquitinbind
site
human
counterpart
suggest
parasit
dub
select
target
inhibitor
base
find
great
interest
explor
antiinfect
opportun
dub
inhibitor
despit
signific
grow
attract
dub
drug
target
dubfocus
drug
discoveri
challeng
research
arena
face
variou
obstacl
first
although
dub
clear
catalyt
pocket
priori
seem
suitabl
drug
develop
key
challeng
identifi
potent
compound
show
select
among
relat
dub
properti
commensur
develop
clinic
use
second
ubiquityl
deubiquityl
intracellular
process
least
present
amen
classic
smallmolecul
chemic
approach
third
dub
execut
transfer
ubiquitin
molecul
via
reactiv
thiol
group
standard
assay
use
identifi
inhibitor
prone
nonselect
redox
alkyl
fals
posit
fourth
mechan
action
dub
enzym
often
complex
involv
regul
enzymat
activ
alloster
effect
andor
substratemedi
catalysi
mani
dub
altern
activ
nonact
conform
see
make
challeng
design
predict
biochem
assay
develop
druglik
compound
final
dub
often
display
specif
ubiquitin
chain
well
target
protein
henc
optim
likelihood
identifi
genuin
inhibitor
prudent
develop
bespok
primari
screen
secondari
assay
recapitul
physiolog
substrat
ubiquitinlinkag
set
dub
despit
issu
dub
fundament
catalyt
driven
protein
known
enzymat
function
present
research
opportun
identifi
smallmolecul
inhibitor
either
within
activ
site
adjac
alloster
pocket
inde
past
year
increas
rate
progress
success
screen
evolv
smallmolecul
dub
inhibitor
develop
one
move
toward
clinic
evalu
exampl
see
tabl
understand
mechan
action
individu
dub
import
initi
screen
subsequ
drug
discoveri
campaign
dub
gener
isopeptidas
case
catalys
proteolyt
reaction
lysin
chain
carboxyl
group
correspond
ubiquitin
c
terminu
last
two
ctermin
amino
acid
residu
glycin
lack
side
chain
result
narrow
linker
either
side
isopeptid
bond
mirror
long
narrow
dub
catalyt
cleft
moreov
cysteinyl
proteas
dub
catalyt
activ
tend
reli
two
three
crucial
residu
compris
catalyt
diad
triad
gener
contain
side
chain
lower
pk
catalyt
cy
lead
nucleophil
attack
ubiquitinsubstr
isopeptid
linkag
collect
properti
bring
complex
identif
select
smallmolecul
inhibitor
target
dub
catalyt
site
like
restrict
breadth
seri
suitabl
develop
potent
select
dub
inhibitor
proteostasi
thiophen
pyrimidin
corederiv
inhibitor
known
bind
ubiquitin
pocket
prevent
ubiquityl
substrat
bind
howev
major
histor
current
dub
drug
discoveri
programm
focus
chemic
seri
includ
provis
activ
warhead
form
revers
irrevers
coval
adduct
dub
catalyt
cystein
high
reactiv
warhead
includ
oxid
alkyl
aryl
moieti
like
limit
drug
select
may
hamper
develop
accept
pharmacokinet
pharmacodynam
paramet
may
also
pose
risk
idiosyncrat
toxic
patient
reason
lessreact
warhead
explor
close
relat
warhead
util
nondub
cystein
proteas
inhibitor
clinic
exampl
inhibitor
identifi
librari
amidomethyl
methyl
acryl
compound
contain
michael
acceptor
group
also
found
rupintrivir
inhibitor
rhinoviru
proteas
gsk
cathepsin
c
inhibitor
addit
inhibitor
ref
contain
michael
acceptor
group
similar
found
principia
biopharma
bruton
tyrosin
kinas
btk
inhibitor
howev
exampl
number
compound
weak
dub
inhibitor
mission
therapeut
discov
coval
activesit
seri
druglik
unrel
previous
describ
dub
inhibitor
achiev
submicromolar
cellbas
potenc
exhibit
good
oral
bioavail
peptidas
includ
mani
cystein
proteas
recogn
small
linearpolypeptid
motif
cleav
either
peptid
bond
dub
howev
complex
dub
cleav
isopeptid
linkag
side
chain
lysin
residu
ctermin
glycin
ubiquitin
isopeptid
linkag
provid
specif
flexibl
mechan
proteolysi
also
dub
need
accommod
substanti
globular
posttransl
modif
ubiquitin
ubl
ubiquitinubl
chain
catalyt
site
furthermor
unlik
cystein
peptidas
catalyt
triad
cysteinyl
peptidas
dub
usual
function
configur
activitybas
probe
abp
tool
incorpor
element
target
modif
andor
detect
label
protein
enabl
assess
enzymat
activ
inhibit
alloster
regul
requir
render
dub
fulli
function
process
alloster
regul
substratemedi
exampl
otulin
trigger
intramolecular
reorgan
exampl
induc
key
cofactor
addit
sever
dub
associ
multiprotein
complex
proteasom
valosincontain
protein
vcp
also
known
signalosom
associ
alloster
regul
affin
dub
substrat
instanc
dub
coexist
complex
ubiqu
ityl
machineri
issu
must
therefor
care
consid
establish
screen
compound
evalu
assay
dub
dub
inhibitor
suggest
target
alloster
site
inhibitor
ref
approxim
twenti
year
ago
gener
assay
establish
measur
dub
enzymat
activ
base
substrat
ubiquitin
ctermin
ubamc
substrat
effici
cleav
hydrolys
variou
dub
releas
highli
fluoresc
amc
moieti
assay
use
variou
dub
inhibitor
screen
exampl
identifi
ref
ref
inhibitor
one
signific
drawback
prone
fluoresc
interfer
exhibit
mani
small
molecul
moreov
amc
altern
tag
rhodamin
tetramethylrhodamin
tamra
use
less
prone
fluoresc
artefact
contain
peptid
linkag
thu
differ
quit
substanti
natur
dub
substrat
process
substrat
thu
requir
dub
function
nonphysiolog
manner
therebi
potenti
diminish
prospect
identifi
compound
oper
cellular
therapeut
set
challeng
develop
dub
inhibitor
screen
assay
oxid
hydrolysi
activesit
cysteinyl
residu
purifi
dub
biochem
buffer
sensit
requir
use
protect
reduc
agent
dithiothreitol
dtt
usual
millimolar
concentr
maintain
dub
enzymat
activ
alter
concentr
type
reduc
agent
exampl
cystein
glutathion
tri
phosphin
tcep
consider
affect
inhibit
obtain
hit
compound
follow
highthroughput
screen
identifi
inhibitor
abil
compound
inhibit
presenc
differ
reduct
evalu
mani
compound
show
greatest
inhibit
absenc
reduct
less
potent
presenc
cystein
glutathion
least
potent
presenc
dtt
tcep
subset
molecul
show
altern
profil
demonstr
inhibit
presenc
dtt
tcep
final
set
molecul
inhibit
addit
reduct
ad
togeth
data
demonstr
critic
natur
reduc
environ
dub
activ
inhibit
thu
screen
base
high
concentr
reduc
agent
use
firstgener
fluoresc
substrat
gener
high
falseposit
rate
issu
like
signific
challeng
identifi
genuin
select
dub
inhibitor
inde
nonselect
natur
dub
inhibitor
highlight
biochem
selectivityprofil
assay
rel
dub
inhibitor
report
literatur
show
promis
studi
matrixassist
laser
desorptionion
timeofflight
malditof
mass
spectrometri
use
screen
dub
activ
specif
systemat
assess
specif
recombin
human
dub
diubiquitin
isom
possibl
chain
linkag
linear
subsequ
panel
dub
screen
report
dub
inhibitor
find
demonstr
none
compound
display
strong
select
toward
singl
dub
mani
inhibit
dub
panel
novel
technolog
base
chemic
synthes
dub
substrat
contain
isopeptid
linkag
ubiquitin
chain
andor
assay
technolog
less
prone
fals
posit
luminesc
timeresolv
fluoresc
mass
spectrometri
advanc
screen
campaign
therefor
exploit
exampl
ubiquitinaminoluciferin
substrat
use
varieti
dub
demonstr
suitabl
assay
window
highthroughput
screen
subsequ
use
repres
dub
demonstr
statist
robust
reagent
screen
campaign
inhibitor
believ
develop
crucial
optim
prospect
identifi
develop
dub
inhibitor
ultim
clinic
use
key
issu
studi
dub
modul
cell
understand
substrat
specif
dub
prefer
monoubiquityl
substrat
wherea
other
favour
specif
ubiquitin
chain
type
chain
bear
mix
linkag
mix
chain
contain
ubiquitin
ubl
furthermor
mani
dub
specif
substrat
protein
mediat
mechan
often
involv
region
dub
distinct
catalyt
site
dub
substrat
determin
biochemistri
yeast
twohybrid
interact
proteom
profil
genet
often
challeng
timeconsum
clearli
abil
directli
monitor
dub
activ
within
nativ
biolog
system
essenti
understand
physiolog
patholog
role
individu
dub
well
effect
dub
inhibit
dub
activ
cell
monitor
chemic
probe
gener
readili
detect
coval
complex
dub
catalyt
site
recent
review
ref
activ
probe
label
dub
base
catalyticsit
thiol
group
dub
reactiv
toward
probe
depend
type
electrophil
warhead
fuse
ubiquitin
addit
profil
dub
level
activ
catalyt
inhibit
activ
probe
also
use
identifi
dub
affin
purif
combin
mass
spectrometri
recent
activitybas
probe
abp
bear
fluoresc
report
tag
gener
replac
initi
tag
exampl
haemagglutinin
ha
epitop
allow
fluoresc
imag
instead
detect
immuno
blot
although
product
ubiquitin
abp
histor
base
trypsincatalys
transpeptid
modifi
ubiquitin
c
terminu
vinyl
sulfon
group
recent
approach
involv
full
chemic
synthesi
ubiquitin
abp
advanc
allow
incorpor
modifi
amino
acid
residu
posit
abp
whether
natur
mass
spectrometri
becom
import
tool
monitor
ubi
quitin
adduct
well
chang
ubiquitin
level
inde
combin
abp
immunoblot
mass
spectrometri
gener
power
tool
monitor
dub
activ
inhibit
small
molecul
well
assess
drugenzym
target
engag
cell
tissu
exampl
one
studi
use
abp
demonstr
select
cell
contrast
inhibit
broad
rang
dub
addit
anoth
studi
demonstr
cellular
select
panel
dub
use
abp
immunoblot
activitybas
proteom
probe
facilit
develop
pharmacolog
activ
enzym
inhibitor
approach
repres
cellbas
assay
treatment
inhibitor
carri
intact
cell
allow
rang
cellular
enzym
assess
simultan
competit
assay
inhibitor
abp
lead
reduc
label
profil
abp
loss
signal
abplabel
target
enzym
allow
assess
specif
inhibit
limit
approach
howev
number
enzym
success
label
abp
represent
activ
enzym
cellular
proteom
abp
use
character
dub
inhibitor
immuno
precipit
combin
identif
labelfre
quantif
mass
spectrometrybas
proteom
use
approach
quantit
data
cellular
dub
obtain
confirm
broad
dub
inhibitor
wherea
found
select
inhibitor
may
therefor
provid
basi
explor
therapeut
opportun
oncolog
see
preced
section
tabl
past
decad
wit
dramat
advanc
understand
dub
function
mechan
action
regul
diseas
linkag
parallel
major
improv
dub
biochem
assay
screen
technolog
lead
develop
increas
number
smallmolecul
dub
inhibitor
whose
select
explor
possibl
refin
inhibitor
provid
basi
druglik
molecul
suitabl
clinic
evalu
also
provid
versatil
tool
investig
dub
cell
biolog
regul
biochem
mechan
well
test
therapeut
hypothes
diseas
model
although
still
earli
predict
extent
broad
therapeut
potenti
dub
next
year
certainli
seem
set
produc
excit
develop
arena
dub
biolog
drug
discoveri
first
report
demonstr
deubiquityl
stabil
reg
cell
